Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers: A combined analysis from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), the International BRCA1 and BRCA2Carrier Cohort Study (IBCCS), and the Breast Cancer Family Registry (BCFR).

Phillips, Kelly‐Anne; Milne, Roger L.; Rookus, M.A.; Goldgar, DE; Friedlander, M.; McLachlan, Sue Anne; Buys, S. S.; Antoniou, Antonis C.; Birch, Kate; Terry, Mary Beth; Easton, DF; Weideman, Prue; Daly, M. de Burgh; Andrieu, Nadine; John, EM; Hooning, MJ; Andrulis, IL; Caldés, Trinidad; Olsson, Håkan; Hopper, John L.

doi:10.1200/jco.2011.29.15_suppl.1500

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2013

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,8 There is growing evidence of the significant reduction of breast cancer incidence from risk-reducing mastectomy 9,10 as well as evidence for medical prevention. 11 Although there has been some debate regarding cancer risk in unaffected noncarriers of a BRCA1 and/or BRCA2 mutation, 12 recent studies suggest that individuals identified as noncarriers can be reassured that their breast/ovarian cancer risk is similar to that of the general population.…”

Section: Introductionmentioning

confidence: 99%